LAVA Therapeutics N.V. (LVTX) Fundamentals

LAVA Therapeutics NV is a biotechnology company. It is focused on transforming cancer treatment by developing a platform of novel bispecific antibodies designed to selectively induce gamma-delta T cell-mediated immunity against tumor cells.
SHARE INFORMATION
Market CapUS$ 70,367,219
Shares Outstanding25,775,538
Float9,455,875
Percent Float36.69%
Short Interest0.00
Short Percent Float0.0%
Short Interest Ratio0.00
Short Interest Date-
Latest Fiscal Dividend Per ShareUS$ 0.00
Latest Fiscal RevenueUS$ 5,443,470
Latest Fiscal EPSUS$ -13.28
Latest Fiscal Date2021-12-31
DIVIDENDS
Dividend (3 Years)US$ 0.00
Dividend (5 Years)US$ 0.00
Ex Dividend Date-
Dividend RateUS$ 0.00
Dividend Yield0.0%
Payment Cash-
HOLDERS
Institutions7
Institutional Holdings Date2022-05-31
Institutional Bought Previous 3 Months429
Institutional Holdings Percent1.6%
Institutional Sold Previous 3 Months-
Insider Holdings Date-
Insider Bought Previous 3 Months-
Insider Holdings Percent0.0
Insider Sold Previous 3 Months-
Insider Shares Owned-
TRADING INFO
52 Week HighUS$ 11.15
52 Week LowUS$ 2.28
52 Week High ChangeUS$ -75.25
21 Day Moving AverageUS$ 2.7757
21 Day Extended Moving AverageUS$ 2.8372
50 Day Moving AverageUS$ 3.3994
50 Day Extended Moving AverageUS$ 3.3137
200 Day Moving AverageUS$ 5.1776
200 Day Extended Moving AverageUS$ 5.2849
10 Day Average Volume9,689
20 Day Average Volume12,616
30 Day Average Volume11,010
50 Day Average Volume8,908
Alpha-0.091919
Beta0.4893
Standard Deviation0.188314
R20.013614
7 Day Price ChangeUS$ 0.45
7 Day Percent Change19.74%
21 Day Price ChangeUS$ -0.36
21 Day Percent Change-11.65%
30 Day Price ChangeUS$ -0.59
30 Day Percent Change-17.77%
Month to Date Price ChangeUS$ -0.27
Month to Date Percent Change-9.0%
Quarter to Date Price ChangeUS$ -1.67
Quarter to Date Percent Change-37.95%
180 Day Price ChangeUS$ -2.37
180 Day Percent Change-46.47%
200 Day Price ChangeUS$ -4.18
200 Day Percent Change-60.49%
Year to Date Price ChangeUS$ -2.77
Year to Date Percent Change-50.36%

LAVA Therapeutics N.V. (LVTX) Key Ratios

PROFITABILITY
EBIT Margin-706.2%
EBITDA Margin-694.2%
Pre-Tax Profit Margin0.0%
Profit Margin Count0.0%
Gross Margin0.0%
Profit Margin TOT0.0%
INCOME STATEMENTS
RevenueUS$ 5,363,789
Revenue Per ShareUS$ 0.2081
Revenue (3 Years)US$ 0.00
Revenue (5 Years)US$ 0.00
FINANCIAL STRENGTH
Price to Tangible Book0.70
Total Debt To Equity0.10
Int Coverage-53.60
Current Ratio7.80
Leverage Ratio1.20
Quick Ratio7.70
Long Term Debt To Capital0.04
VALUATION MEASURES
PE Ratio-1.80
Enterprise ValueUS$ -48,692,782
Price to Sales13.1189
Price to Free Cash-2.00
PE High Last 5 Years0.00
Price To Book0.70
Price To Cash Flow0.00
PE Low Last 5 Years0.00
Price to Tangible Book0.70
MANAGEMENT EFFECTIVENESS
Receivables Turnover4.70
Invoice Turnover0.00
Assets Turnover0.10
Return Assets-25.66
Return on Equity-30.90
Return on Capital-28.55

LAVA Therapeutics N.V. (LVTX) Profile

PROFILE INFO
Issue TypeCS
SEC Type-
AuditorPricewaterhouseCoopers Accountants N.V.
CEOStephen A. Hurly
Emplyoees58
Last AuditUQ
CIK0001840748
IndustryBiotechnology
SectorHealthcare
NAICS-
CONTACT INFO
AddressYalelaan 60
Utrecht, UT 3584 CM
Websitehttps://www.lavatherapeutics.com
Facsimile-
Telephone+31 850163100
Email-
Your Recent History
NASDAQ
LVTX
LAVA Thera..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:au D:20220627 18:38:06